×
About 1,074 results

ALLMedicine™ Agammaglobulinemia Center

Research & Reviews  479 results

Bruton's agammaglobulinemia tyrosine kinase (Btk) regulates TPA‑induced breast cancer c...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962096
Oncology Reports; Kim JM, Park J et. al.

Mar 24th, 2021 - Bruton's agammaglobulinemia tyrosine kinase (BTK) is an important cytoplasmic tyrosine kinase involved in B‑lymphocyte development, differentiation, and signaling. Activated protein kinase C (PKC), in turn, induces the activation of mitogen‑activa...

Atypical Presentation of Severe Fungal Necrotizing Fasciitis in a Patient with X-Linked...
https://doi.org/10.1007/s10875-021-01017-3 10.1038/361226a0 10.1006/clim.2002.5241 10.1034/j.1600-065X.2000.17809.x 10.1046/j.1365-2141.2001.02905.x 10.1097/01.md.0000229482.27398.ad 10.1016/j.jaip.2015.12.015 10.1016/j.jaci.2020.03.001 10.5114/aoms.2016.60338 10.1016/S0147-9571(02)00051-6 10.1111/ped.13453 10.1016/j.clim.2019.108328 10.1093/bioinformatics/bty897 10.1038/nmeth.2890 10.1016/j.gene.2015.02.019 10.1016/B978-0-12-404748-8.00009-5 10.1007/BF03401778 10.1093/hmg/3.10.1751 10.1073/pnas.91.19.9062 10.1126/scisignal.2004298 10.1074/jbc.M104828200 10.7554/eLife.06074 10.1007/s10875-019-00737-x 10.1093/mmy/myy136 10.1097/MOP.0000000000000031 10.3389/fimmu.2018.02337 10.1038/s41598-017-06342-5 10.1111/j.1600-0854.2012.01382.x 10.1016/j.mib.2020.07.001 10.3389/fimmu.2017.01454 10.1093/cid/cix687 10.1182/blood-2017-11-818286 10.1093/cid/ciy175 10.1016/j.waojou.2019.100018 10.1182/blood-2010-04-281170 10.1016/j.semcdb.2018.03.020 10.3324/haematol.2019.219220 10.3324/haematol.2016.152017 10.1080/1040841X.2020.1751060 10.1186/s12879-019-3941-3 10.1128/JCM.01646-10 10.1099/jmm.0.062174-0 10.1128/JCM.05095-11 10.4103/ijo.IJO_389_18 10.1099/jmmcr.0.000044 10.1080/23744235.2016.1239027 10.1155/2019/6253829 10.12932/AP0304.31.4.2013
Journal of Clinical Immunology; Chear CT, Nallusamy R et. al.

Mar 13th, 2021 - X-linked agammaglobulinemia is a rare primary immunodeficiency due to a BTK mutation. The patients are characteristically deficient in peripheral B cells and serum immunoglobulins. While they are susceptible to infections caused by bacteria, enter...

An 11-Year-old Male With X-linked Agammaglobulinemia and Persistent Abdominal Pain.
https://doi.org/10.1097/INF.0000000000003056
The Pediatric Infectious Disease Journal; Fettinger NB, Bradley JS et. al.

Mar 12th, 2021 - Metagenomic next-generation sequencing is a promising tool for detecting pathogens that are difficult to isolate by traditional modalities, particularly in the diagnosis of complex infections in immunocompromised children. We describe a child with...

The Clinical Course of COVID-19 Pneumonia in a 19-Year-Old Man on Intravenous Immunoglo...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912932
The American Journal of Case Reports; Almontasheri A, Al-Husayni F et. al.

Feb 22nd, 2021 - BACKGROUND Since the emergence of coronavirus disease 2019 (COVID-19), patients with the illness have presented with considerable variation in severity. Some infected individuals present mild or no symptoms, while others present severe illness wit...

Agammaglobulinemia with normal B-cell numbers in a patient lacking Bob1.
https://doi.org/10.1016/j.jaci.2021.01.027
The Journal of Allergy and Clinical Immunology; Kury P, Staniek J et. al.

Feb 11th, 2021 - Agammaglobulinemia with normal B-cell numbers in a patient lacking Bob1.|2021|Kury P,Staniek J,Wegehaupt O,Janowska I,Eckenweiler M,|

see more →

Drugs  39 results see all →

Clinicaltrials.gov  541 results

Bruton's agammaglobulinemia tyrosine kinase (Btk) regulates TPA‑induced breast cancer c...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962096
Oncology Reports; Kim JM, Park J et. al.

Mar 24th, 2021 - Bruton's agammaglobulinemia tyrosine kinase (BTK) is an important cytoplasmic tyrosine kinase involved in B‑lymphocyte development, differentiation, and signaling. Activated protein kinase C (PKC), in turn, induces the activation of mitogen‑activa...

Gammagard liquid - immune globulin infusion (human) injection, solution-Baxalta US Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d42adca-0dd7-4df7-864d-5a7feee52130

Mar 21st, 2021 - GAMMAGARD LIQUID is indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age or older. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agamm...

Cuvitru - immune globulin subcutaneous (human) injection, solution-Baxalta US Inc
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9aad7ec9-6097-4805-8f1b-898bec35f218

Mar 21st, 2021 - CUVITRU is an Immune Globulin Subcutaneous (Human) (IGSC), 20% Solution indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age and older. This includes, but is not limited to, co...

Atypical Presentation of Severe Fungal Necrotizing Fasciitis in a Patient with X-Linked...
https://doi.org/10.1007/s10875-021-01017-3 10.1038/361226a0 10.1006/clim.2002.5241 10.1034/j.1600-065X.2000.17809.x 10.1046/j.1365-2141.2001.02905.x 10.1097/01.md.0000229482.27398.ad 10.1016/j.jaip.2015.12.015 10.1016/j.jaci.2020.03.001 10.5114/aoms.2016.60338 10.1016/S0147-9571(02)00051-6 10.1111/ped.13453 10.1016/j.clim.2019.108328 10.1093/bioinformatics/bty897 10.1038/nmeth.2890 10.1016/j.gene.2015.02.019 10.1016/B978-0-12-404748-8.00009-5 10.1007/BF03401778 10.1093/hmg/3.10.1751 10.1073/pnas.91.19.9062 10.1126/scisignal.2004298 10.1074/jbc.M104828200 10.7554/eLife.06074 10.1007/s10875-019-00737-x 10.1093/mmy/myy136 10.1097/MOP.0000000000000031 10.3389/fimmu.2018.02337 10.1038/s41598-017-06342-5 10.1111/j.1600-0854.2012.01382.x 10.1016/j.mib.2020.07.001 10.3389/fimmu.2017.01454 10.1093/cid/cix687 10.1182/blood-2017-11-818286 10.1093/cid/ciy175 10.1016/j.waojou.2019.100018 10.1182/blood-2010-04-281170 10.1016/j.semcdb.2018.03.020 10.3324/haematol.2019.219220 10.3324/haematol.2016.152017 10.1080/1040841X.2020.1751060 10.1186/s12879-019-3941-3 10.1128/JCM.01646-10 10.1099/jmm.0.062174-0 10.1128/JCM.05095-11 10.4103/ijo.IJO_389_18 10.1099/jmmcr.0.000044 10.1080/23744235.2016.1239027 10.1155/2019/6253829 10.12932/AP0304.31.4.2013
Journal of Clinical Immunology; Chear CT, Nallusamy R et. al.

Mar 13th, 2021 - X-linked agammaglobulinemia is a rare primary immunodeficiency due to a BTK mutation. The patients are characteristically deficient in peripheral B cells and serum immunoglobulins. While they are susceptible to infections caused by bacteria, enter...

An 11-Year-old Male With X-linked Agammaglobulinemia and Persistent Abdominal Pain.
https://doi.org/10.1097/INF.0000000000003056
The Pediatric Infectious Disease Journal; Fettinger NB, Bradley JS et. al.

Mar 12th, 2021 - Metagenomic next-generation sequencing is a promising tool for detecting pathogens that are difficult to isolate by traditional modalities, particularly in the diagnosis of complex infections in immunocompromised children. We describe a child with...

see more →

News  11 results

Dyspnea and Night Sweats in a 46-Year-Old Man
https://reference.medscape.com/viewarticle/732961_3

Jan 14th, 2020 - Which of the following is the most likely diagnosis? Your Peers Chose: Bruton agammaglobulinemia 0% Thymoma 0% Pheochromocytoma 0% Teratoma 0% Discussion The patient in this case was eventually diagnosed with thymoma. Symptoms from a thymoma or th...

FDA OKs Immunoglobulin Xembify for Primary Immunodeficiencies
https://www.medscape.com/viewarticle/915280

Jul 4th, 2019 - The US Food and Drug Administration (FDA) has approved a 20% immune globulin solution for subcutaneous injection (Xembify, Grifols) to treat primary immunodeficiencies in patients as young as 2 years old, according to a company statement. The appr...

FDA approves IVIG product for PI and chronic ITP
https://www.mdedge.com/hematology-oncology/article/186860/anemia/fda-approves-ivig-product-pi-and-chronic-itp
HT Staff

Feb 9th, 2017 - Vials of product Photo by Bill Branson The US Food and Drug Administration (FDA) has approved an intravenous immunoglobulin (IVIG) product (Gammaplex® 10%) for the treatment of primary immunodeficiency (PI) and chronic immune thrombocytopenia (ITP.

FDA approves IVIG product for kids
https://www.mdedge.com/hematology-oncology/article/187717/pediatrics/fda-approves-ivig-product-kids
HT Staff

Aug 7th, 2015 - Vials of drug Photo by Bill Branson The US Food and Drug Administration (FDA) has approved an intravenous human immune globulin (IVIG) product (Gammaplex) for pediatric patients age 2 years and older who have primary humoral immunodeficiencies. Th.

Octagam Withdrawn From Market Over Unresolved Blood Clots, Embolisms
https://www.medscape.com/viewarticle/729411

Sep 23rd, 2010 - September 24, 2010 — Octapharma USA is voluntarily withdrawing all lots of immune globulin G (IgG) intravenous (human) 5% liquid preparation (Octagam) in the United States while it investigates blood clots and embolisms linked with the biologic, t...

see more →

Patient Education  4 results see all →